Flashpoint Therapeutics is developing nanostructure-based therapeutics that kinetically tune and co-deliver precise combinations of therapeutic components to target cells. The company’s proprietary discovery platform, built on roughly 10 years of nanotechnology research from Chad Mirkin’s laboratory at Northwestern University, enables controlled stoichiometry, optimized structure–function relationships, and synchronized activation kinetics. Preclinical results reported include 35x increased co-delivery to immune cells, 80x stronger immune activation, and 650% greater tumor killing versus conventional formulations, and a proof-of-concept clinical study demonstrated delivery of nucleic acid cargo to the brain. Flashpoint’s initial candidate is a first-in-class cancer immunotherapy; the company plans to nominate a second development candidate and advance multiple internal and partnered discovery programs. The platform is positioned to enhance RNA, peptide, and CRISPR therapeutics and to be licensed or partnered with companies in those areas. The newly announced financing will support moving candidates toward the clinic, expanding the team, and enhancing the platform.

Total raised

$10M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2023